A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors

Study D7880C00001 is a first-in-human (FIH), Phase 1, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of MEDI9253 in combination with durvalumab in adult participants with select advanced/metastatic solid tumors.

Inclusion Criteria

Inclusion Criteria: 1. Participant must be at least 18 years old at signing of informed consent. 2. Body weight > 35 kg at screening. Exclusion Criteria: 1 Primary central nervous system (CNS) disease is excluded, as well as untreated or uncontrolled metastatic CNS involvement, leptomeningeal disease, or cord compression. NOTE: CNS disease that has been treated and stable/controlled for at least 3 months is permitted. Participants with CNS disease controlled via systemic steroids are not permitted.

Additional locations may be listed on ClinicalTrials.gov for NCT04613492.

United States

Pennsylvania

Pittsburgh

University of Pittsburgh Cancer Institute (UPCI)

Status: Active

Name Not Available

Up to approximately 192 participants may be assigned to study intervention in the study

across approximately 30 sites globally.

Trial PhasePhase I

Trial Typetreatment

Lead OrganizationAstraZeneca Pharmaceuticals LP

Primary IDD7880C00001
Secondary IDsNCI-2020-13138, 2020-002294-96
ClinicalTrials.gov IDNCT04613492

A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors

Inclusion Criteria

United States

Pennsylvania

Pittsburgh

Have a question?
We're here to help

Which trials are right for you?

A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors

Description

Eligibility Criteria

Locations & Contacts

Trial Objectives and Outline

Trial Phase & Type

Lead Organization

Trial IDs

Have a question?We're here to help

Which trials are right for you?

Have a question?
We're here to help